Big Buttons

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

• Education (and CE) from USP

  For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →

• Compounding post-Chevron

  At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →

• 503B sourcing: our state-by-state analysis

  Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →

• What we’ll be talking about at CCH

  When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.  read more →

More News

A joint APC-NCPA letter submitted last week to the FDA Center for Veterinary Medicine’s Dr. Bill Flynn includes more than two dozen questions on which the associations seek great clarity regarding the agency’s animal compounding GFI.

“We believe your answers can provide much-needed clarity on how the agency views the processes enumerated in the guidance document and can help compounding pharmacists, veterinarians, and state boards of pharmacy better understand how the agency will view compliance with the GFI,” the letter states. “We also believe that the questions contained in this letter demonstrate the range and depth of what is as yet unknown about the effect and enforcement of the GFI, and therefore support the recent joint letter submitted by several pharmacy trade associations requesting an enforcement delay on the GFI until at least FY2024.”

APC intends to communicate Flynn’s responses to our members and other stakeholders so that they can build processes and SOPs to attain compliance with GFI 256.